Abstract-Protein signaling networks play a central role in transcriptional regulation and the etiology of many diseases. Statistical methods, particularly Bayesian networks, have been widely used to model cell signaling, mostly for model organisms and with focus on uncovering connectivity rather than inferring aberrations. Extensions to mammalian systems have not yielded compelling results, due likely to greatly increased complexity and limited proteomic measurements in vivo. In this study, we propose a comprehensive statistical model that is anchored to a predefined core topology, has a limited complexity due to parameter sharing and uses micorarray data of mRNA transcripts as the only observable components of signaling. Specifically, we account for cell heterogeneity and a multilevel process, representing signaling as a Bayesian network at the cell level, modeling measurements as ensemble averages at the tissue level, and incorporating patient-to-patient differences at the population level. Motivated by the goal of identifying individual protein abnormalities as potential therapeutical targets, we applied our method to the RAS-RAF network using a breast cancer study with 118 patients. We demonstrated rigorous statistical inference, established reproducibility through simulations and the ability to recover receptor status from available microarray data.
INTRODUCTION
C ELLS are complex molecular machines contained within phospholipid membranes that isolate a unique chemical environment. A key component of the cellular machinery is the set of protein signaling networks, which permit a cell to sense the internal and external environments and respond by altering metabolism and gene expression. Signaling networks comprise interacting signaling pathways, with each pathway containing a number of individual signaling proteins.
Signaling proteins can modify their behavior based on conformational changes induced by other signaling proteins. In the typical case, a kinase (a protein capable of adding a phosphate group to a protein) modifies its target protein by adding phosphate groups at serine or threonine amino acid residues. The modified protein undergoes a conformational change, activating its own kinase activity, leading to modification of a new target protein. This chain of phosphorylation causes a signal to be transduced through the cytosol of the cell, resulting in changes in enzymatic activity or activation or suppression of a transcriptional regulator (i.e., a transcription factor or cofactor). In addition to kinases, there are phosphatases that remove phosphate groups, thus reversing the signal from a kinase. Also, for certain signaling proteins, activity is generated by cleavage of a parent protein or dimerization, which is especially common for receptor tyrosine kinases that reside on the cell membrane and respond to external environmental cues, such as hormones or growth factors.
Statistical Network Modeling
Biological data are inherently probabilistic and generally display hierarchical relationships. Statistical analysis is then a logical approach for modeling large-scale molecular networks and for identifying specific nodes within a signaling network that are optimal therapeutic targets. In particular, graphical Markov models, such as Bayesian networks, have gained considerable interest lately in biomedical research because they naturally accommodate hierarchical network structure and reduce model identification to estimating lowdimensional conditional distributions.
However, despite their early promise, few major insights have emerged from such modeling efforts, at least for mammalian data. It is likely many of the problems that have arisen in applying Bayesian networks to these data arise from the high dimensionality of the data and, in the case of reverse-engineering regulatory networks, from the necessity of learning both the underlying topology and estimating the corresponding statistical parameters. As a result, methods designed to reduce what needs to be learned from data by incorporating prior knowledge have come into use. They are even more required when, like in the present study, small sample sizes come in combination with a large proportion of unobservable components in the process of interest.
In particular, in the work described here, in order to apply graphical Markov models to learning signaling networks, we utilize existing knowledge about biological wiring diagrams as well as sharply reduce dimensionality by parameter-sharing. In addition, we account for cell heterogeneity by modeling the observed expression data as cell averages. Recent evidence on TRAIL-induced cell death suggests that variability in protein concentrations between even clonal cells can lead to phenotypic variation that homogeneous models cannot address [14] . Our approach yields a stable model which can be identified with current sample sizes.
Wiring Diagram
Unlike standard Bayesian network approaches, which attempt to learn a wiring diagram in addition to statistical parameter estimates, we begin with a defined core signaling network, thus eliminating the combined problem of insufficient sample size and of hidden components for determining parameters for our statistical models.
A number of the core pathways of protein-protein interactions have been detailed, especially those affecting disease, for example in cancer studies [24] , [28] . Since these pathways play critical roles in embryogenesis across many organisms, there is a substantial knowledge base [11] . For any given system, the core pathways need to be modified in terms of specific cell types, which is presently best done through review of the literature [18] . In this way, a core signaling network can be created for a system of interest, with the pathways considered critically linked to transcriptional regulators.
More specifically, studies on mutation in breast cancers have verified driver mutations of key signaling components in multiple pathways that lead to breast cancer development [17] . Both the RAS-RAF proliferation pathway and the PI3K cell fate pathways have multiple driver mutations, suggesting these are excellent targets for studies aimed at developing a method suitable for identifying targets for therapeutic intervention. With such applications in mind, we constructed a network based on the core signaling processes in breast cancer. The resulting network is shown in Fig. 1 , with a hierarchical layout, where cell receptors (rounded squares) are on top as initiators of signaling; signaling proteins (circles) and transcription factors (diamonds) are in the middle; and genes (octagons) are at the bottom as final targets.
We then identified a public domain microarray data set from a breast cancer study that included phenotypic information on receptor status [3] . This data set was collected using the Affymetrix U133A GeneChip and deposited in ArrayExpress (TABM158) [22] . We annotated the network in Fig. 1 for the targets of the transcription Fig. 1 . Graphical representation of the signaling network of interest. Cell receptors (rounded squares) are roots along with cellular conditions (hexagons) and sit on top of the network as initiators of downstream signaling. Signaling proteins (circles) followed by transcription factors (diamonds) appear in the middle of the hierarchy. Genes (octagons) are leaves of the network and appear at the bottom as final targets of transcription. The types of causal interaction between components are depicted with arcs directed from parent to child; arrow and round heads are used to indicate activation and inhibition, respectively.
factors from TRANSFAC Professional v11.4 [19] using our annotation pipeline, associating Affymetrix probes with Unigene clusters for gene identification [12] . These data will be used to learn the parameters of our Bayesian network and to validate the learned model by deducing the status of upstream signaling proteins in the form of probabilities of activation, comparing the estimated activation levels with ground-truth obtained from the clinical status measurements provided in [22] .
A Multilevel Model
Applying Bayesian networks directly to the graph in Fig. 1 is not straightforward for several reasons. First, this ignores an important component of the data acquisition process, which is that the measured transcript levels are averaged over large ensembles of cells. Taking this into account in the model induces notable differences compared to what would correspond to a single cell model. In a proper tissue-level model, each observation arises from a large group of networks, each representing a cell. Second, the status of the signaling proteins is not observed. The only observed variables are tissue-level (hence cell-averaged) gene expression levels. Despite the averaging and hidden variables, we are still able to predict the receptor status given the observed transcript levels.
Our model is organized on two levels, the first one incorporating cell-dependent variables, and the second one including factors that are common to large cell assemblies (tissues), but are subject-dependent. An overview is presented in Fig. 2 .
At the cell level, we model signaling pathways as Bayesian networks in which the information is flowing from receptors (which constitute the roots of the networks to which are added certain cellular conditions, such as hypoxia) to genes. This process is assumed to be working within each cell, independently of the others. With an additive noise component, a gene expression measurement is modeled as the logarithm of a linearly increasing function of total gene-specific RNA abundance summed over a large population of cells. Final transcript readouts constitute the only observable components in our model.
The parameters of the Bayesian network at the cell level are assumed to be identical within each subject. This implies that the measurements stem from sums of independent and identically distributed random variables. Most of these parameters are also assumed to be identical across subjects, with the exception of the cell receptor activation Fig. 2 . Illustration of a microarray experiment. A tissue sample obtained from a test subject is assumed to contain a large ensemble of cells. Signaling in each cell is modeled by the same Bayesian network that generates gene-specific mRNA, independently of other cells given the patient's phenotypic receptor activation probabilities. The mRNA accumulated from all cells is processed through hybridization, scanning, etc., to yield the final gene expression readouts, which constitute the only observable variables. Thus, the overall process motivates our multilevel approach and the assumption that measured gene expression levels are proportional to their single-cell conditional expectations given patient-dependent root activation probabilities.
probabilities. These probabilities are subject-dependent and assumed to be randomly generated. Putting things in a generative order, we model the process leading to a microarray measurement as the following sequence of operations, performed independently for each subject:
1. Specify the receptor activation probabilities. These are shared by all cells in the analyzed tissue. 2. For each cell, let the gene expression be obtained from the state of the terminal nodes in a Bayesian network that models the signaling pathway. 3. For each gene, define the total expression to be the sum of the gene expressions over a large population of cells. 4. The final expression measurement is modeled as the logarithm of a linearly increasing function of this total expression with some additive observation noise.
Organization of the Paper
Our paper is organized as follows: In Section 2, we review previous related work on cell signaling networks. In Section 3, we lay out our statistical model in detail, elaborating the cell, tissue, population, and measurement levels. Then, in Section 4, we present the learning algorithm for model identification, with applications and experiments discussed in Section 5. Finally, some conclusions are drawn in Section 6.
RELATED WORK
Bayesian network models have been used in a wide variety of ways. For example, the relationships between nodes do not need to represent actual physical connections; consequently, Bayesian networks can model the effects of clinical variables on outcome, even relying on molecular data as well [18] . This can be viewed as a phenomenological perspective, where we abstract away the direct molecular causative agents, but retain predictive relationships between measured variables [5] , [27] . Bayesian networks have also been used to model traditional genetic networks, such as with time series data, where the upregulation of a gene is identified as a causative agent for expression of other genes [6] . Other approaches to creating robust models might be attempted. Ordinary differential equation (ODE) models, such as modeling of ERBB signaling response [1] , can capture great complexity, but they rely on large numbers of poorly determined parameters. This can limit their provability, since large ranges of parameter values on many components must be explored to guarantee uniqueness. Alternatively, networks can be reconstructed from limited measurements of protein state and abundance, such as from flow cytometry [25] , or from prior data on beliefs of connectivity [20] . In these cases, the goal is to construct the connectivity and flow of the network for a small number of proteins from proteomic measurements.
For inference on larger cell signaling networks, a number of alternative methods have been used. Matrix factorization has been used to determine activity on components of networks or in biological processes from microarray data, such as through Network Component Analysis [16] and other methods reviewed in [13] . Bayesian methods have been applied to estimate gene regulatory networks from microarray data [21] , from microarray data coupled to other information such as protein-protein interactions [9] , and from proteomic measurements of signaling species in the networks [20] .
Our work has two substantial differences to this previous work. First, we introduce the ensemble of cell models concept that captures biological heterogeneity. Second, we build a Bayesian network that realizes the molecular interactions of the biological network as reflected in transcriptional changes that can be measured routinely and globally.
A COMPREHENSIVE MODEL

Individual Cell Model
Interacting signaling pathways of an individual cell are modeled as a Bayesian network over a predetermined directed acyclic graph G G ¼ ðV ; EÞ, where V is the set of nodes (or vertices) and E is the set of oriented edges. The graph used in this paper is depicted in Fig. 1 . Some nodes v 2 V represent a protein which participates in signal transduction, namely a cell receptor, intermediate signaling protein or transcription factor (TF). Other nodes stand for a cellular condition, such as DNA damage and Hypoxia, and the terminal nodes (those with no children) represent genes, the final targets of signal transduction.
A directed edge ðu; vÞ 2 E, from u toward v (u; v 2 V ), represents a potential functional interaction between u and v. Each such edge is labeled with the type of regulation, either activating (upregulating) or inhibitory (downregulating). Let paðvÞ ¼ fu : ðu; vÞ 2 Eg denote the set of v's parents, i.e., nodes that have an edge toward v. Accordingly, let A v and I v denote the disjoint subsets of paðvÞ consisting of the parents that activate and inhibit v, respectively.
We denote by R & V the set of roots of the network, i.e., the nodes with no parents, which can be either cell receptors or certain cellular conditions which initiate downstream signaling. Also, let G & V stand for the terminal nodes of G G; clearly G \ R ¼ ; (since there are no isolated nodes). While v will usually denote a generic node, we will use whenever possible r to denote a receptor node and g to represent a gene.
Each node v 2 V carries a random variable X v , which quantifies the signaling activity of node v in network. We will use smallcase letters (e.g., x v ) for realizations of random variables, and we will write X B to indicate the set of random variables fX v ; v 2 Bg. For example, X G is the set of variables associated with genes. These random variables are interpreted as follows: For each gene g 2 G, X g stands for the expression level of gene g in the cell, i.e., the amount of transcribed mRNA. All other variables X v ; v 2 V n G are binary, and represent the state of signaling at node v, where X v ¼ 0 means "off" and X v ¼ 1 means "on," interpreted as the presence of signal at site v, ready to propagate down. The stochastic process X V ¼ fX v : v 2 V g is our representation of signaling activity in a single cell, and we encode the joint distribution in a Bayesian network. Therefore, the probability that the whole system is in state
Turning to the parameterization of the model, consider first the root nodes r 2 R; since X r is binary, there is one parameter per node, denoted r ¼ p r ð1Þ ¼ P ðX r ¼ 1Þ. For transitions, for each v 2 V , we attribute a function v : f0; 1g jpaðvÞj ! ½0; 1 which quantifies the net effect of the collection of signals x paðvÞ from the parents of v. The extreme values, 0 and 1, correspond to pure inhibition and pure activation, respectively. More precisely,
. If v is neither a root nor a terminal node,
which completely specifies the transition probability at v. They are "hard wired" in our model. . If g 2 G, the only property of the distribution of mRNA abundance X g that will be needed is the conditional expectation given the parent TFs. We then introduce a scaling coefficient a g > 0 and take
We can interpret this as follows: transcription is either "on" or "off" with probability g ðx paðgÞ Þ. When it is "on," the mean is a g and when it is "off" the abundance is zero. A possible choice, if v is not a root, is to take
It is easy to see that v is linearly increasing in the difference between the number of active upregulating and downregulating parents of v, which is clearly an oversimplified model of "transcriptional synergy," at least in the case of "competing" parents. More complex forms could be considered which are more faithful to the chemical interactions, perhaps even accounting for TF binding energies. However, in our particular network, only a relatively small portion of nodes have competing parents and our choice like (2) has the major advantage of being parameter-free, allowing one to precompute certain quantities which appear repeatedly during parameter identification. Moreover, simulating the Bayesian network is significantly more efficient under the assumption of linearity in (2) (see Section 3.5).
Tissue Model
At the patient level, the measured abundance of mRNA for each gene on the microarray originates from a very large ensemble of cells contained in the sample tissue. Let C denote this ensemble of cells, with size C ¼ jCj, and let x g;c be amount of transcribed mRNA for gene g 2 G in cell c 2 C. The total abundance is denoted by x g;C ¼ P c x g;c . By the law of large numbers, assuming the Bayesian networks for the cells are independent, we have
where a g and R ¼ f r : r 2 Rg are the model parameters that affect X g . In addition, due to the Markov property of the network,
for the expected transcription rate of gene g given the root activation probabilities R , and dropping the approximation above, the transcript abundance in the tissue is
Population Level
It is not realistic to assume that the activation rates of the receptors and cellular conditions at the roots of the network are the same for every subject. Consequently, the final component of the model is to consider these rates to be subject-dependent, in fact random variables at the population level. That is, there is a random variable È with parameters a r and b r .
Measurement Model
It is well known that the actual measurement process, i.e., the steps leading up to what is actually recorded for each gene and patient, is complex, and should take into account the various stages of a microarray experiment including hybridization, scanning, background correction, and normalization. As reported by numerous authors [7] , [8] , [10] , we assume a linear relationship between scanned intensities of expression and actual RNA abundances. In particular, after undergoing all these steps, we consider the final log-expression reading y ðnÞ g , obtained for gene g 2 G and subject n ¼ 1; . . . ; N, to be the logarithm of a linearly increasing function of the corresponding tissue mRNA abundance x ðnÞ g;C , say
The gain parameter c ðnÞ g represents the net factor, that comes between patient n's actual molecule count for gene g and its processed probe intensity, before being transformed to logscale. It involves the multiplicative measurement noise and accounts for experimental effects like hybridization efficiency, scanner gain, and normalization. On the other hand, the additive term b ðnÞ g stands for the part of the intensity, that does not stem from the experimented mRNA, but rather effects like unspecific hybridization, detector offset, etc.
Analyzing this representation in further detail with individual roles of the aforementioned steps and taking noise into account (see Appendix A), (5) can be approximated by
where g is an offset parameter-specific to gene g; and ðg;nÞ is an i.i.d. realization of the measurement noise which, in log-scale is assumed to be an additive and zero mean Gaussian random variable with subject and gene-independent variance 2 . In summary, our overall model, as illustrated in Fig. 2 , incorporates the entire process from the Bayesian network modeling of individual cell signaling, to patient-to-patient differences in receptor activation, to log-expression readouts at the population level. As a result, the final observation made for gene g for a given patient is modeled as a Gaussian random variable Y g with conditional mean g þ log g ð R Þ, parameterized by the gene-dependent offset g and subjectdependent root activation rates R ¼ f r : r 2 Rg, and each r has a Beta distribution with node-specific parameters a r and b r . The level of transcriptional regulation g ð R Þ for target g is evaluated using the single-cell Bayesian network model. Finally, the variance 2 accounts for the variation in measurement error, which is the same for all genes.
Expected Transcription Rate Function
Recall from (3) that for each gene g 2 G, g ð R Þ represents the cell-level average transcription rate of g, where we interpret this equation as a conditional expectation given the root activation rates are fixed to be R . Let R g denote the set of roots which are ancestors of g, so that g ð R Þ only depends on Rg . Since these root variables are binary and independent,
Consequently,
It will be important in the following to have a quick access to the value of g ð R Þ for any given choice of the root activation rates. One possibility is to precompute all the coefficients of the above polynomial expression (i.e., all the E½ g ðX paðgÞ ÞjX Rg ¼ x Rg ), which are parameter-free, and evaluate the polynomial when needed. This is tractable as long as 2 jR g j remains manageable, which is the case with our network where jR g j does not exceed five. The precomputation of the conditional expectations has to be done only once. It can be done exactly for small networks (including, again, our case), or for specific topologies. In the general case, approximate (and often good) values can be computed using belief propagation methods, or Monte Carlo sampling. When jR g j is too large for this strategy to be tractable, it is still possible to compute or approximate g ð R Þ for a given R using belief propagation each time its value is needed (without precomputation).
Finally, we notice that the computation of g can be done very efficiently when, for each v 2 V , the function v depends linearly on the states x paðvÞ of the parents. This property is true, in particular, in the model proposed in (2) . In that case, g can be evaluated using dynamic programming along the network's top-down hierarchy, thanks to the following proposition, proved in Appendix B. Thus, in the case of proposition 3.1, it suffices to precompute coefficients d rg for r 2 R and g 2 G to ensure a computation of g ð R Þ in a time which is linear in the number of roots.
LEARNING ALGORITHM
Our model has both observed and hidden variables. The observed ones are the gene expression levels y G ¼ fy ðnÞ g : g 2 G; n ¼ 1; . . . ; Ng over N subjects. All other variables are unobserved. Among these, we are particularly interested in the root activation rates È R ¼ f ðnÞ r : r 2 R; n ¼ 1; . . . ; Ng, which constitute the hidden phenotypic information about the individuals in the population. The joint density of gene expression values and activation rates is given by
where refers to the parameters of the model. For each gene g 2 G, the conditional density of corresponding log-expression Y g is Gaussian
with an offset g and noise variance 2 . For each root node r 2 R, the corresponding activation rate r has a standard beta prior
In summary, the parameters to be inferred are ¼ f g ; a r ; b r ; 2 : g 2 G; r 2 Rg, which includes the shape parameters ða r ; b r Þ of the beta priors on receptor activation rates, the variance 2 of additive measurement noise, and the offset parameters g for gene expressions. The beta parameters are specific to each individual receptor, but constant across the patient population. The noise variance is constant for all genes and patients. Gene offsets are specific to each individual gene but constant across subjects.
Model identification, i.e., learning is based on observed expression data y G , where we assume each Y g to be conditionally independent of expressions Y Gnfgg of other genes, given activation rates R . Hidden components that we represent in the cell level, namely the signaling proteins g (g 2 G) .
The standard method for learning such a latent variable model is the expectation maximization (EM) algorithm. Briefly, EM provides an improving sequence ð ðtÞ Þ t!1 of parameter estimates by iteratively maximizing the conditional expectation of the complete data log-likelihood, given i.i.d. incomplete observations. In particular, each iteration t of EM involves 1) an E-step which requires computing of the missing data posterior, f RjG ðÈ R jy G ; ðtÞ Þ, in order to evaluate the current objective function
and 2) an M-step, in which one solves for the new parameter estimateŝ ðtþ1Þ ¼ arg max
by maximizing the objective function. This procedure is repeated until convergence is evident.
Evaluating (9) is usually simplified when the likelihood of the complete model (including both hidden and observed variables) belongs to an exponential family, which is the case here, since we can write log f GR ðy G ; È R jÞ ¼ ÀÃðÞ þ hÅðÞ; Sðy G ; È R Þi; where hÁ; Ái denotes the vector scalar product; Ã and Å are scalar and vector valued functions of ; and Sðy G ; È R Þ is a vector-valued complete data-sufficient statistic. Explicit formulas for Ã, Å, and S are provided in Appendix D. The maximum likelihood estimator can be expressed as a function of the sufficient statistic, in the form S 7 ! ML ðSÞ:
The computation of ML ðSÞ with our model is described in Appendix E. Since (9) can be rewritten as
it follows that the E-step can be reduced to computing the conditional expectation of the sufficient statistic, namely
while the M-step is simply given bŷ
However, due to the marginal beta distribution of È R , there is no simple closed form for the computation of (10) in the E-step and straightforward EM is intractable here. Instead, we will consider a stochastic variant, the Stochastic Approximation EM (SAEM) algorithm, wherein the E-step is approximated with Monte Carlo integration. Under mild conditions [4] , [15] , SAEM converges to (local) maxima of the objective function if the complete data log-likelihood belongs to a curved exponential family, which is the case in our model. Basically, SAEM replaces the E-step of conventional EM with a stochastic approximation running in parallel, involving the simulation of missing data È R . In its simple form, the SAEM algorithm makes an iterative approximation of S ðtþ1Þ by definingŜ 
In principle, in order to ensure the convergence of the SAEM algorithm, one should take P 1 t¼1 ðtÞ ¼ 1 and
So the SAEM algorithm replaces computing conditional expectations by sampling from the conditional distribution which is most of the time much more feasible. Moreover, variants of this algorithm allow for coupling the iterations with Markov chain Monte Carlo sampling, when direct sampling is not feasible or not efficient (which is the case for our model). One can also use more than one sample È ðtÞ R at each step, using a sample average in (12) . The explicit implementation of the variant we have used is described in the next sections, for a single iteration t. Þ m!1 of realizations will then constitute a Markov chain, whose stationary distribution is the soughtafter posterior f RjG .
Simulation
For each r 2 R, let G r be the set of genes which are descendants of r and let R r be the set of root nodes other than r which have a descendant in G r . It is not hard to show (see Appendix C) that the conditional density of r given the rest of the variables ðY G ; Rnfrg Þ only involves quantities indexed from G r [ R r . Hence, letting f rjG r R r denote this univariate conditional, the mth realization ðn;t;mÞ R of missing root variables for subject n and iteration t of SAEM, is produced by Gibbs sampling as follows: This step is made explicit in Appendix C.
Stochastic Approximation
We update the sufficient statistic according tô 
Maximization
We compute ðtþ1Þ ¼ ML ðŜ ðtþ1Þ Þ, the latter function being described in Appendix E. In summary, the model parameters are efficiently learned by keeping track of complete data sufficient statistics, which are improved with new realizations of missing data.
Root Activation Probabilities
The sequences ðÈ ðt;mÞ R Þ t!1;m!1 that are generated by the SAEM algorithm can also be used to estimate, subjectdependent, expected root activation probabilities given corresponding gene expression levels. 
EXPERIMENTS WITH THE RAS-RAF NETWORK
In this section, we present experiments in learning the network, measuring the stability of model identification, and estimating the states of the hidden variables, especially the activation states of the receptors. Our data consist gene expression levels measured for 38 genes and collected from 118 breast cancer patients. The observed genes, i.e., the targets of the signaling network of Fig. 1 , are again listed in Table 1 , together with their known transcription factors and associated type of regulation. The data set also contains complete measurements for the ER status of patients.
Validating Identifiability of Model
Before discussing experiments with real patient data, we first verify that the model can be accurately identified from artificial gene expressions simulated with known parameters. Given the parameter vector , we generate subjectdependent receptor activation rates È R ¼ f ðnÞ r : r 2 R; n ¼ 1; . . . ; Ng according to their beta priors f R ðÁjÞ; and, conditioned on these rates, we sample gene expressions y G ¼ fy ðnÞ g : g 2 G; n ¼ 1; . . . ; Ng from f GjR ðÁjÈ R ; Þ. We then evaluate the fit between true parameter vector and the estimate that is learned by applying the algorithm to the simulated observations y G . In particular, since the SAEM algorithm also returns predictionsÈ R of receptor activation rates, we can compare those subject-specific estimates with their simulated true counterparts È R that are kept hidden during learning.
We can also conduct the above procedure at different noise levels. Note that, with simulated phenotypes È R , our model assumes that the log of expected transcription rates log g ðÈ R Þ ¼ flog g ð ðnÞ R Þ : n ¼ 1; . . . ; Ng is the noise-free signal that determines the subject-dependent variation for each gene g 2 G. Letting log g ¼ P n log g ð ðnÞ R Þ=N denote the corresponding sample average, and given the variance 2 of the measurement noise, the signal-to-noise ratio (SNR), measured in dB, is found by SNR ¼ 10 log 10 Table 2 provides a summary of how accurately the activation rates are estimated at different SNR levels. For each r 2 R, the correlation coefficients between the simulated true vector ½ are given as an average score over 10 independent experiments per choice of SNR, where the experiments differ in the random selections of the true parameters used to simulate data of sample size N ¼ 100. Clearly, the model is accurately identified with moderately sized learning samples and even with SNR ¼ 0, where the standard deviation in log g ð R Þ averaged across all genes g 2 G, i.e., the root-mean squared amplitude of the subjectdependent signal is the same as that of noise. In particular, the estimates of the receptors ER and EGFR inferred from simulated data are more precise since they affect the majority of the genes observed. Fig. 1 bottom) ; the type of regulation (activating or inhibiting) is indicated by the arrows.
Estimating Receptor Activity from Real Data
One important way to measure the utility of the model is to estimate the states of the receptor proteins from the gene expression data. In our model, these states are binary variables, each sampled independently from a patientdependent activation rate. Consequently, it is these rates which are the more natural targets of estimation. For each of the 118 patients, we are provided with a binary label for the measured phenotypes, either "ER-positive" or "ERnegative." Our activation rate estimates f ðnÞ ER g N n¼1 are scalars. The rank-sum test, also known as Mann-WhitneyWilcoxon test, offers a natural and robust way to compare predictions, especially by averaging over different parameter initializations. It is a nonparametric procedure for testing the hypothesis that two independent samples are identically distributed.
Let ER þ ; ER À & f1; 2; . . . ; Ng be the subpopulations of patients who are ER-positive and ER-negative, respectively. In our case, the null hypothesis H 0 is that the activation rates from these two subpopulations are identically distributed. Our data are the estimated ratesÈ The data set also reproduces the EGFR status for 79 of the 118 patients, again recorded as EGFR-positive or EGFRnegative, but with only eight positives. The same rank-sum test approach to correlate this information and the EGFR rate predicted by the model, failed to provide a significant p-value, but this would have been very hard to achieve due to limited power of rank-sum test with such a small number of available EGFR-positive patients.
Estimating the States of Other Signaling Proteins
Given predictions for receptor activation rates, we can also deduce the subject-dependent states of the nonreceptor components, i.e., signaling proteins and transcription factors that are not explicitly involved in (8) . Having for each patient n, the subject-specific expected status" x ðnÞ v ¼ E½X v j ðnÞ R of each network component v 2 V n G can be directly evaluated similar to the way in which we computed the g s in (7) . Letting R v denote the root ancestors of v, we get
where, again, the expectations involved in the sum are parameter-free and can be precomputed using Proposition 3.1. Note that, with that notation, subject n's expected status" x ðnÞ r at a root r 2 R is the same as the prediction of the corresponding activation rate ðnÞ r . For a node v with only one parent, say u, the above computation simplifies to"
In other words, along linear sequences, signaling is assumed to propagate deterministically, where each node either copies or reverses the status of its single parent. Thus, our model is invariant to adding/removing components at such pathways. That is, topologies that reduce to the same collapsed structure yield the same data likelihood as well as the same predictions for common nodes. Fig. 4 shows a gray-scale heat map (black: low, white: high) of estimates for hidden components appended to the observed gene expressions, where, to avoid redundancy, hidden nodes with only one parent are excluded. As mentioned above, these can be directly deduced from the ones already shown. Spot ðv; nÞ gives the estimated or observed status of signaling component v, for patient n. Each row is scaled to a common dynamic range by subtracting the mean and normalizing with standard deviation. Columns (i.e., patients) are arranged according to the rank of the projection of the corresponding gene profile onto the direction of largest variation in gene space, namely the first eigenvector of the covariance matrix of observations. Besides demonstrating our ability to estimate the subject-dependent status of cell signaling, further analysis of this picture is limited by the absence of ground truth for hidden nodes. However, it is noteworthy that our inference of hidden nodes aligns with the first order variation among genes.
Validating Reproducibility and Sensitivity to Sample Size
In order to assess the method's generalization power and sensitivity to sample size we used a "repeated random subsampling validation" procedure, where we repeatedly partitioned the available gene expression data into two random halves, and checked the fit between models learned from these two disjoint subsets. In order to describe this validation study, let B & f1; . . . ; Ng be a subpopulation of patients and let is already an output of our learning algorithm, and it is found in the same way by (15) . Now, let A and A c be two disjoint halves of the experimented population f1; . . . ; Ng. To validate our method, we want to compare, for each n, the estimationŝ from two disjoint sets of subjects. Table 3 shows the reproducibility results, where for each r 2 R, we give the corresponding scatter plot of 
Validating Robustness with Respect to Realistic Modifications in Network Topology
In Section 5.3, we discussed the invariance of statistical inference under structural perturbations such as collapsing or elongating linear pathways. Denoting the original core topology of Fig. 1 by G G, we now examine the robustness of our model with respect to biologically realistic revisions e G G which are similar to G G but not equivalent in the previous sense of collapsed chains.
As another plausible representation of the signaling network, consider the modified wiring diagram e G G of Fig. 5 . Note that, compared with G G, e G G lacks a few genes that were originally observed, as well as several proteins and connections. Absent components and their discarded pathways are shown in light gray for a better visualization of the difference.
On the same gene expression data, we ran our algorithm using the revised topology e G G and compared the new estimations to their counterparts found with G G. Fig. 5 also quantifies the resulting agreement of inference for nodes that are common under both models. Attached to each v and averaged over 20 independent experiments, we give the correlation coefficient between the subject-dependent status estimations ½" x ðnjG GÞ v N n¼1 and ½" x ðnj e G GÞ v N n¼1 based on respective structures G G and e G G, and evaluated according to (16) . The magnitude of the correlations demonstrates the robustness of the model with respect to different wiring assumptions that are biologically reasonable.
DISCUSSION AND CONCLUSION
Cell signaling processes play a central role in the etiology of many diseases, and signaling proteins provide a logical target for therapeutic intervention with numerous therapeutics under development [24] . The success of imatinib mesylate (IM, Gleevec) in treating chronic myelogenous leukemia has greatly increased the hope for targeted therapy, however, these new targeted therapeutics are designed to disrupt a single signaling protein. As studies in glioblastoma multiforme have demonstrated, each individual tumor has a different specific set of aberrant signaling proteins [23] , [26] , making it essential to identify in each individual which proteins need to be targeted for treatment.
The logical method to identify an aberrant signaling protein is to look for changes in protein posttranslational modifications (PTMs), since most signal propagation takes the form of phosphorylation changes in proteins or cleavage events changing protein localization and structure. However, these measurements are presently very limited in vivo. An alternative approach is to use the mature microarray technology targeted at mRNA transcripts, since transcriptional changes resulting from activation or suppression of transcriptional regulators are primary end points for many signaling processes. Microarray data coupled to models of signaling networks provide a potential avenue for identification of individual signaling protein abnormalities.
We have designed a statistical model for cell signaling, which accounts for cell heterogeneity, can be robustly learned from available microarray data and supports rigorous statistical inference. Our effort was mainly invested in laying out a comprehensive framework to identify and quantify aberrations in signaling. Consequently, we used prior knowledge and considered a documented core topology (Fig. 1 ) that is particular to our breast cancer study and available expression data. We followed a multilevel approach to elaborate the overall generative process starting from hidden phenotypes to final log-expressions with different statistical interpretations in cell, tissue, population, and measurement levels.
It is worth noting here that, for computational purposes, we constructed our Bayesian network formulation at the cell level, with parameter-free, linear, and generic transition probabilities as given in (2), which, it may be argued, oversimplify the underlying chemical processes. However, the overall model allows the user to incorporate his/her expert knowledge and to explain signaling dynamics with more complex, nonlinear choices, which in turn may enhance the predictive accuracy of the method. In fact, without sacrificing efficiency, one can assume alternative formulations to (2) that are still linear but favor the known dominance of one or more competing parents at crossing pathways; or, for instance, one can differentiate interactions at the signaling level from those at the level of transcription. To further enrich the model, one can even introduce extra parameters that can be validated as more protein data becomes available.
Note also that, due to lack of measurements on all hidden variables but ER, the biological validation of our model remains currently very limited. On the other hand, ER ground truth usually correlates with the majority of the genes. Thus, if the task were to predict ER statuses only, one would argue for simpler Bayesian approaches with performances comparable to ours. However, this argument should not lessen the utility of our model which lays out a comprehensive framework to infer on each hidden component. In that regard, our ER predictions we report here, should not be interpreted as an achievement, which otherwise could not be made, but rather a consistency check.
Finally, we have demonstrated model's identifiability, reproducibility through simulations and robustness under biologically meaningful revisions of topology. Using real patient data, we validated its ability to recover receptor status in a breast cancer study. As signaling plays a central role in the etiology of many diseases, identification of the aberrant proteins driving signaling errors will provide information for personalized therapeutic intervention. It is expected that this will improve patient prognosis and reduce undesirable side effects during treatment.
APPENDIX A MEASUREMENT PROCESS
As argued in [2] , [7] , we first assume the additive part b ðnÞ g of (5) is negligibly small due to background correction applied by scanner's imaging software. Second, again proposed by the same authors, we consider a multiplicative decomposition for the gain factor c 
We interpret each component as follows: Combined with the scanner gain, d g represents the background corrected hybridization efficiency of the probe set assigned to gene g. The quantity D ðnÞ , on the other hand, stands for the normalization constant applied across all probes of patient n. We take d g to be gene-specific and fixed for all subjects, whereas D ðnÞ to be subject-dependent and the same for all genes. We further assume that D ðnÞ is proportional to the number C ðnÞ of cells contained in subject n's experimented tissue, since it is usually set to the total intensity captured from the corresponding array. Finally, the remaining variation in c ðnÞ g is attributed to a multiplicative error term given as an exponential, whose argument is modeled i.i.d. for all genes and subjects, and realized as ðg;nÞ for gene g and patient n.
Combining (4), (5), and (17), we obtain (6), i.e., our measurement model for log expression of gene g and patient n y
where, probe-specific parameters and the ratio C ðnÞ =D ðnÞ , which is constant by assumption, are absorbed by the final readout offset g ¼ log
, that is specific to gene g and independent of patients. In log scale, measurement noise becomes additive and described as a zero mean Gaussian random variable with variance 2 , which is the same for all genes and subjects.
APPENDIX B PROOF OF PROPOSITION 3.1
The result follows from the Markov property of the process and the linearity of the expectation. The complete data log-likelihood is log f GR ðy G ; È R jÞ ¼ ÀÃðÞ þ hÅðÞ; Sðy G ; È R Þi:
In our case, functions Ã and Å are given by
with sufficient statistic 
APPENDIX E COMPLETE DATA MAXIMUM LIKELIHOOD
We here give the expression of the maximum likelihood estimator ML in function of the sufficient statistic S Fig. 6 . A simple DAG with five roots and five leaves. Markov Blanket of the white node is the set of black nodes.
described in (18) 
denote the two-and five-dimensional subvectors of the sufficient statistic in (18) , corresponding to root r 2 R and gene g 2 G, respectively. The corresponding maximum likelihood estimator ML is given as follows:
. where ðxÞ ¼ À 0 ðxÞ=ÀðxÞ is the digamma function. A closed-form solution to that system does not exist, but, similar to standard maximum likelihood parameter estimation of a beta density,â r andb r are found numerically. . For each gene g 2 G, the corresponding updated offset parameter is given bŷ
g À s
g :
. Finally, the noise variance is obtained bŷ 2 ¼ 1 jGj 
APPENDIX F THE RANK-SUM TEST FOR ESTIMATING RECEPTOR STATUS
The rank-sum test is performed by first ranking each sample ðnÞ ER in ascending order within the union of both populations. The test statistic U is the sum of the ranks coming from the "negative" population È À ER . (The choice of which rank-sum is immaterial and leads to the same pvalue.) Since both N þ and N À are sufficiently large, U is approximately normal under H 0 , with mean
and standard deviation
We expect that the populationÈ À ER to generate smaller activation rates than the populationÈ þ ER . Consequently, the alternative hypothesis H 1 states that U has a smaller mean than U and the corresponding p-value is the left tail area of normal density N ð U ; 2 U Þ determined by the observation U ¼ u; that is, the probability P H 0 ðU uÞ of observing a test statistic U as small or smaller than the actual rank-sum u found forÈ À ER under the null hypothesis.
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